We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

By LabMedica International staff writers
Posted on 27 Jul 2026

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. More...

Type I interferons are central to host defense, yet their failure in critical illness has been difficult to explain. Clarifying this mechanism could guide risk assessment for viral infections that continue to burden health systems. New findings demonstrate how pre-existing immune factors can disable type I interferon activity in people who developed severe COVID-19.

At the University of Sharjah, investigators and international collaborators found that an affinity-matured autoimmune B‑cell response generates antibodies capable of neutralizing type I interferons. Under normal conditions, these cytokines alert neighboring cells and initiate antiviral programs; however, the study shows that in a subset of patients, the antibodies target interferon‑α and interferon‑ω and block their function. The work identifies three principal B‑cell epitopes spanning all major regions of type I interferons, explaining the breadth of neutralization.

The team combined patient‑derived monoclonal antibodies with X‑ray crystallography and AlphaFold3‑based structural analyses to map antibody–interferon interactions in detail. Extensive somatic hypermutation and evidence of prolonged affinity maturation were observed, indicating a mature, organized autoimmune response rather than a transient byproduct of severe infection. Researchers examined hundreds of antibodies, revealing how this response can exist silently prior to viral exposure and then undermine innate defenses at infection onset.

According to the authors, the findings help explain why some individuals progressed to life‑threatening disease during SARS‑CoV‑2 infection and may be relevant to other respiratory viruses, including seasonal influenza. The study is global in scope, with contributors from universities and research institutes across France, Switzerland, Canada, Spain, Belgium, Saudi Arabia, Sweden, Denmark, Italy, the U.S., Estonia, and the United Arab Emirates. The work was published in Cell.

“The researchers found that these patients had a large and diverse population of B cells specifically programmed to recognize interferons,” said Rabih Halwani, professor of immunology at the University of Sharjah. “Importantly, this abnormal immune response was detectable before the patients developed life-threatening viral disease, suggesting that it was not simply a consequence of severe infection but rather a pre-existing defect that may have contributed to the patients' vulnerability.”

Related Links
University of Sharjah


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.